SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Kitov Pharmaceuticals Holdings LTD To Contact The Firm

NEW YORK, March 28, 2017

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Kitov American Depositary Receipts ("ADRs") pursuant to the Company's initial public offering on or about November 20, 2015 (the "IPO") and/or between November 20, 2015 and February 3, 2017 (the "Class Period").  The case, Pilgaonkar v. Kitov Pharmaceuticals Holdings Ltd et al, No. 1:17-cv-00917 was filed on February 07, 2017, and has been assigned to Judge Lorna Gail Schofield.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) the Company and its Chief Executive Officer ("CEO"), Isaac Israel, published misleading information regarding the Company's clinical trials for its lead drug candidate, KIT-302; and (ii) as a result, Kitov's public statements were materially false and misleading at all relevant times.

Specifically, on February 6, 2017, the Israeli publication, Calcalist, reported that the Company's CEO, Isaac Israel, had been detained and questioned by the Israeli Securities Authority ("ISA") on suspicion of publishing misleading information in connection with a clinical trial of KIT-302. On this news, Kitov's ADRs fell from a closing price of $2.88 on February 3, 2017 to a closing price of $2.55 on February 6, 2017 —a $0.33 or a 11.46% drop.

Then, on February 7, 2017, the NASDAQ suspended trading of the Company's ADRs.  Later on February 7, 2017, the Company informed investors of the aforementioned ISA investigation.

Request more information now by clicking here: www.faruqilaw.com/KTOV . There is no cost or obligation to you.

Take Action